JP2021527061A5 - - Google Patents
Info
- Publication number
- JP2021527061A5 JP2021527061A5 JP2020567972A JP2020567972A JP2021527061A5 JP 2021527061 A5 JP2021527061 A5 JP 2021527061A5 JP 2020567972 A JP2020567972 A JP 2020567972A JP 2020567972 A JP2020567972 A JP 2020567972A JP 2021527061 A5 JP2021527061 A5 JP 2021527061A5
- Authority
- JP
- Japan
- Prior art keywords
- dione
- ethoxy
- phenyl
- methyl
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382402.8 | 2018-06-06 | ||
| EP18382402 | 2018-06-06 | ||
| PCT/IB2019/054744 WO2019234690A1 (en) | 2018-06-06 | 2019-06-06 | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527061A JP2021527061A (ja) | 2021-10-11 |
| JP2021527061A5 true JP2021527061A5 (enExample) | 2022-06-14 |
| JP7510170B2 JP7510170B2 (ja) | 2024-07-03 |
Family
ID=62716011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567972A Active JP7510170B2 (ja) | 2018-06-06 | 2019-06-06 | ５－［［４－［２－［５－アセチルピリジン－２－イル］エトキシ］ベンジル］－１，３－チアゾリジン－２，４－ジオンおよびその塩の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210228558A1 (enExample) |
| EP (1) | EP3801517A1 (enExample) |
| JP (1) | JP7510170B2 (enExample) |
| KR (1) | KR20210031867A (enExample) |
| CN (1) | CN112823004A (enExample) |
| AU (1) | AU2019283650A1 (enExample) |
| BR (1) | BR112020024939A2 (enExample) |
| CA (1) | CA3102584A1 (enExample) |
| CL (1) | CL2020003163A1 (enExample) |
| EA (1) | EA202092954A1 (enExample) |
| IL (1) | IL279186A (enExample) |
| MX (1) | MX2020013182A (enExample) |
| SG (1) | SG11202012095XA (enExample) |
| WO (1) | WO2019234690A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| MX2020013181A (es) | 2018-06-06 | 2021-02-26 | Minoryx Therapeutics S L | Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. |
| HUE071482T2 (hu) | 2018-06-06 | 2025-08-28 | Minoryx Therapeutics S L | (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra |
| CN116390725A (zh) * | 2020-04-30 | 2023-07-04 | 米尼奥尔克斯治疗有限公司 | 用于治疗肺部炎症和间质性肺病的羟基吡格列酮 |
| WO2022243435A1 (en) * | 2021-05-19 | 2022-11-24 | Abliva Ab | Kl1333 for use in medicine |
| WO2024231881A2 (en) * | 2023-05-09 | 2024-11-14 | Minoryx Therapeutics S.L. | Polymorphic forms and formulations of leriglitazone |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3579049B2 (ja) | 1992-04-30 | 2004-10-20 | インスティチュート・パスツール | Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓにおける抗生物質耐性の迅速検出法 |
| GB0030845D0 (en) * | 2000-12-18 | 2001-01-31 | Smithkline Beecham Plc | Novel treatment |
| GB0510469D0 (en) * | 2005-05-23 | 2005-06-29 | Leuven K U Res & Dev | Insulin sensitization to slow down pubertal tempo and to augment pubertal growth |
| AU2012203941A1 (en) * | 2006-06-27 | 2012-07-26 | Sandoz Ag | New method for salt preparation |
| EP2436381A1 (en) * | 2006-06-27 | 2012-04-04 | Sandoz AG | Crystallization of hydrohalides of pharmaceutical compounds |
| WO2013040419A1 (en) * | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| CA2941562C (en) | 2013-03-14 | 2021-09-21 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| NZ725492A (en) | 2014-04-02 | 2023-06-30 | Minoryx Therapeutics S L | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| WO2017083739A1 (en) * | 2015-11-13 | 2017-05-18 | The Trustees Of Columbia University In The City Of New York | A method for predicting a subject's response to valproic acid therapy |
| CN110198945B (zh) | 2016-12-23 | 2023-06-27 | 米尼奥尔克斯治疗有限公司 | 用于制备噻唑烷二酮化合物及其盐的方法 |
-
2019
- 2019-06-06 MX MX2020013182A patent/MX2020013182A/es unknown
- 2019-06-06 AU AU2019283650A patent/AU2019283650A1/en not_active Abandoned
- 2019-06-06 SG SG11202012095XA patent/SG11202012095XA/en unknown
- 2019-06-06 EP EP19742913.7A patent/EP3801517A1/en active Pending
- 2019-06-06 CA CA3102584A patent/CA3102584A1/en active Pending
- 2019-06-06 KR KR1020207037942A patent/KR20210031867A/ko not_active Abandoned
- 2019-06-06 BR BR112020024939-4A patent/BR112020024939A2/pt not_active Application Discontinuation
- 2019-06-06 EA EA202092954A patent/EA202092954A1/ru unknown
- 2019-06-06 US US16/972,366 patent/US20210228558A1/en not_active Abandoned
- 2019-06-06 JP JP2020567972A patent/JP7510170B2/ja active Active
- 2019-06-06 WO PCT/IB2019/054744 patent/WO2019234690A1/en not_active Ceased
- 2019-06-06 CN CN201980046666.1A patent/CN112823004A/zh active Pending
-
2020
- 2020-12-03 IL IL279186A patent/IL279186A/en unknown
- 2020-12-04 CL CL2020003163A patent/CL2020003163A1/es unknown
-
2023
- 2023-09-01 US US18/460,197 patent/US20240091210A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527045A5 (enExample) | ||
| US8202905B2 (en) | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | |
| JP7510170B2 (ja) | ５－［［４－［２－［５－アセチルピリジン－２－イル］エトキシ］ベンジル］－１，３－チアゾリジン－２，４－ジオンおよびその塩の使用 | |
| EP4309738A2 (en) | Method of treating medulloblastoma with an ezh2 inhibitor | |
| US20100076037A1 (en) | Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma | |
| EP3280405B1 (en) | Inhibitors and their uses | |
| US20250064791A1 (en) | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases | |
| JP7549344B2 (ja) | 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法 | |
| JP2022059650A (ja) | 筋萎縮性側索硬化症治療剤及び治療用組成物 | |
| JP2025504963A5 (enExample) | ||
| US12102644B2 (en) | Compounds and methods of promoting myelination | |
| US5462965A (en) | Use of heterocyclic amino-alcohol compounds for treatment of CNS diseases | |
| EP3044192B1 (en) | Deuterated compounds | |
| US20260053777A1 (en) | Use of nrf2 activators for the treatment of cerebral small vessel disease | |
| HK40049546A (en) | Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione | |
| HK40042762A (en) | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts | |
| WO2024245371A1 (zh) | 一种组合产品、盐及其用于治疗神经退行性疾病或病症的用途 | |
| EA047194B1 (ru) | Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей | |
| US20110178100A1 (en) | Apoptosis inhibitor | |
| CN119684283A (zh) | 吡咯并[2,3-c]吡啶类化合物及其用途 |